The right drug, to the right patient, at the right time. As pharma, biotech, diagnostic and technology providers strive to develop more safe and effective precision medicine products that better target patient responders, discover and translate novel predictive biomarker signatures into clinically validated companion diagnostic assays for their precision medicine candidates.
Bringing together thought leaders and pioneers in the biomarker, CDx and precision medicine fields, the BDx portfolio provides much needed platforms for candid conversations on how to define, adopt and implement a CDx strategy to ensure your drug candidates are regulatory compliant, achieve reimbursement and gain market share.
“Great work! It was evident by the professionals who attended and presented, that people are there to make a difference in the CB/CDx world. ”
Senior Sales Executive, Quansys Biosciences